Welcome to this Alexion-sponsored symposium on Complement Component 5 Inhibitor Therapies (C5IT) reviewing Neuromyelitis Optica Spectrum Disorder (NMOSD) with an expert faculty including Prof. Orhan Aktas (Germany), Prof. Noriko Isobe (Japan), & Prof. Ahmed Obeidat (USA).

Symposium Objectives

• Review the role of the complement system in the pathophysiology of anti-aquaporin-4 antibody-postive (AQP4-Ab+) NMOSD
• Explore efficacy and safety highlights from clinical experience and real-world evidence with ravulizumab and eculizumab
• Discuss best practices from clinical experience in treating patients with ravulizumab and eculizumab

SOLIRIS^® (eculizumab) is indicated for the treatment of NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.

ULTOMIRIS^® (ravulizumab) is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive.

Ravulizumab EU Summary of Product Characteristics
Eculizumab EU Summary of Product Characteristics

Prescribing information may differ from country to country. Please refer to your locally approved label and take this into consideration when viewing this information.

Please verify reimbursement status applicable in your country.

Healthcare professionals are asked to report any suspected adverse reactions. Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following email: https://contactazmedical.astrazeneca.com/